Thoracic Malignancies

Hemostasis/Thrombosis

Questions discussed in this category

How do you counsel patients on the risk of thromboembolic complications with use of immunotherapy in NSCLC?

Given recent data in Blood (Moik et al, 2021), and the potentially overlapping risks with other clinical factors associated with NSCLC. Will you alte...

3 Answers available

Papers discussed in this category

The New England journal of medicine, 2016-11-10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-05-31

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-06-14

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Lancet (London, England), 2019-05-04

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Lung cancer (Amsterdam, Netherlands), 2012-12

Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer.

N Engl J Med,

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Blood,

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.

Cancers (Basel), 2019 Dec 25

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

Thoracic Malignancies

Hemostasis/Thrombosis

Questions discussed in this category

Papers discussed in this category

Related Topics in Thoracic Malignancies